Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor

Eitemau Tebyg

• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2012)
• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2013)
• Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2013)
• Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs
  gan: Lin, Jessica J., et al.
  Cyhoeddwyd: (2015)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2016)